Compare Sanofi SA (SNY) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.07. The key difference: Sanofi SA pays a 5.55% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Sanofi SA is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SNY | TLT | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | — |
52-Week High | $52.34 | $92.06 |
52-Week Low | $41.33 | $82.05 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
TLT (iShares 20+ Year Treasury Bond ETF) trades at $82.11, showing minimal daily movement with a 0.08% gain. The technical outlook remains bearish with moving averages signaling strong selling pressure, while oscillators indicate neutral momentum. Recent news highlights pressure from rising Treasury yields and concerns about US debt levels approaching $40 trillion, with institutional activity showing Ferguson Shapiro LLC acquiring 37,900 shares in the latest quarter.
The ETF faces headwinds from rising long-term yields and inflation concerns, though recent dividend payments provide income support. Key risks include Federal Reserve policy uncertainty and escalating geopolitical tensions affecting bond markets. Investors should monitor inflation data and Treasury yield movements for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
